Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide plus Canagliflozin in T2DM
NCT02324842Completed
- Sponsor
- UT Health San Antonio
- Start
- Nov 2014
- Primary completion
- Mar 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of canagliflozin and liraglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by UT Health San Antonio. Primary endpoints: Hemoglobin A1c at 4 months and Fasting Plasma Glucose at 4 months. Started Nov 2014; status: completed.
02
Drugs
canagliflozinliraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02324842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02324842.